Biogen (NASDAQ: BIIB) exec logs RSU conversions and stock moves

Rhea-AI Filing Summary

Biogen Inc. Head of Corporate Development Adam Keeney reported multiple equity transactions dated February 6, 2026. He acquired 1,802 and 3,278 shares of common stock at $0 per share through the exercise of restricted stock units, then disposed of 589 and 994 shares at $201.18 per share.

Following these transactions, Keeney directly beneficially owned 5,881 shares of Biogen common stock and 6,557 restricted stock units. The restricted stock units referenced in the filing vest in three equal annual installments starting one year after their respective grant dates in 2024 and 2025.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Keeney Adam

(Last) (First) (Middle)

BIOGEN INC.

225 BINNEY STREET

(Street)

CAMBRIDGE MA 02142

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
BIOGEN INC. [ BIIB ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Head of Corporate Development

3. Date of Earliest Transaction (Month/Day/Year)
02/06/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	02/06/2026		M		1,802	A	$0	4,186	D
Common Stock	02/06/2026		F		589	D	$201.18	3,597	D
Common Stock	02/06/2026		M		3,278	A	$0	6,875	D
Common Stock	02/06/2026		F		994	D	$201.18	5,881	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Restricted Stock Unit	$0	02/06/2026		M			1,802	(1)	02/07/2027	Common Stock	1,802	$0	1,802	D
Restricted Stock Unit	$0	02/06/2026		M			3,278	(2)	02/06/2028	Common Stock	3,278	$0	6,557	D

Explanation of Responses:

1. The restricted stock units vest in three (3) equal annual installments, commencing one year after the grant date of 02/07/2024.

2. The restricted stock units vest in three equal yearly installments beginning on the first anniversary of the grant date of February 6, 2025.

	/s/ Wendell Taylor, attorney-in-fact for Mr. Keeney	02/10/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transactions did Biogen (BIIB) report for Adam Keeney?

Biogen reported that Adam Keeney acquired common shares via restricted stock unit exercises and disposed of some shares on February 6, 2026. After these moves, he directly held 5,881 Biogen common shares and 6,557 restricted stock units.

How many Biogen (BIIB) shares does Adam Keeney own after this Form 4?

After the reported transactions, Adam Keeney directly beneficially owned 5,881 shares of Biogen common stock. He also held 6,557 restricted stock units, which represent future rights to receive additional shares as they vest over time.

What prices were involved in Adam Keeney’s Biogen (BIIB) share transactions?

The filing shows common shares acquired at $0 per share through restricted stock unit exercises and dispositions at $201.18 per share. These prices reflect the accounting treatment for equity awards and the value used for the reported share disposals.

What do the restricted stock units in Biogen (BIIB) Form 4 represent?

The restricted stock units give Adam Keeney the right to receive Biogen common shares as they vest. One grant vests in three equal annual installments starting February 7, 2025, and another in three yearly installments beginning on February 6, 2026.

What role does Adam Keeney hold at Biogen (BIIB) in this Form 4?

In this Form 4, Adam Keeney is identified as an officer of Biogen, serving as Head of Corporate Development. The reported equity transactions relate to his position and associated stock-based compensation awards at the company.